Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fess is a leading brand of non-medicated saline nasal sprays and washes, primarily marketed in Australia and New Zealand. The product line is designed to relieve nasal congestion associated with sinusitis, hay fever, the common cold, and allergies. Its mechanism of action is physical and osmotic; the saline solution thins and loosens thick nasal mucus, making it easier to clear from the nasal passages, while also moisturizing the nasal mucosa to prevent irritation. Originally developed by Care Pharmaceuticals, the brand was acquired by Prestige Brands Holdings (now Prestige Consumer Healthcare) in 2013. The Fess portfolio includes various formulations tailored for different age groups, including infants (FESS Little Noses) and adults, as well as hypertonic solutions for more severe congestion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium chloride (Care Pharmaceuticals).